Navigation Links
Global Bone Cement and Accessories Market Is Set to Expand from $630 Million in 2013 to Over $1 Billion by 2022
Date:9/3/2014

BURLINGTON, Mass., Sept. 3, 2014 /PRNewswire/ -- Decision Resources Group finds that the global market for bone cement and accessories will expand from $630 million in 2013 to over $1 billion by 2022. While the United States will continue to be the largest contributor of global revenues, the most growth will come from the rapidly expanding Brazilian, Indian and Chinese markets, where joint reconstruction volumes are increasing quickly and thus boosting demand for bone cement and accessories.

Other key findings from Decision Resources Group's coverage of the global bone cement and accessories market:

  • Impact of cementless implants: Although the bone cement market will be hampered by the use of cementless implants, the once rapid shift to cementless devices has slowed. Recent budget and reimbursement cuts have caused physicians to question whether the benefits of cementless implants justify their higher cost over cemented implants.
  • Premium-priced products: Despite pricing pressures, some higher-priced bone cement and accessory products will be increasingly adopted. For example, more expensive antibiotic bone cement is gaining popularity due to its ability to reduce the potential for infection. Higher-priced compatible and enclosed vacuum systems are also being adopted because they minimize the amount of monomer fumes in the operating room and reduce cement porosity.
  • Antibiotic bone cement in Japan: In 2014, the first antibiotic bone cement products—from Stryker and Biomet—entered the Japanese market, which will have a favorable impact on revenue growth. However, use of the products will be limited because they are only approved for very specific indications in Japan and there is a lack of awareness of antibiotic bone cement in the country.

Comments from Decision Resources Group Lead Analyst Deanna Edmunds:

  • "Stryker continues to lead the global market for bone cement and accessories, and the top players are all larger multinational companies that also sell related products, specifically reconstructive joint implants."
  • "The competitive landscape could see some change going forward. Zimmer's pending acquisition of Biomet could boost the combined company's position in the reconstructive implant space, which would have a positive impact on its position in the market for bone cement and accessories."

Additional Resources:

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:
Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cambrex To Present At Rodman & Renshaw 16th Annual Global Investment Conference
2. CytoSorbents to Present at the 2014 Rodman & Renshaw Annual Global Investment Conference
3. Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
4. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
5. Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
6. Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology
7. Global Markets and Technologies for Molecular Imaging Devices
8. Bariatric Surgery: Global Markets for Services and Devices
9. Acute Heart Failure Global Clinical Trials Review, H2, 2014
10. Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden
11. Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... consumer insights on healthcare, announced today that it has ... report Cool Vendor in Life Sciences, 2016, ... 15, 2016.  The report focuses on life-science- oriented analytics, ... insight from patients and doctors, confirm medication ingestion, and ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, ... Lifecycle Management Solutions (VLMS) today announced that ... services for sufferers of chronic kidney failure ... to manage their corporate validation process. The ... a software solution to manage their validation ...
(Date:4/27/2016)... 2016   ... sur le trimestre, soutenu par une croissance de ... Croissance de +16% des ventes aux hôpitaux et ... Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de ... son chiffre d,affaires pour le premier trimestre clos ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... A new ... with severe congenital diaphragmatic hernia have better survival rates if surgery is performed ... (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs into ...
(Date:4/29/2016)... PA (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the ... Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent Marketing ... an exercise invention which aids in proper muscle development. , "The Gym & ... Creative Director of World Patent Marketing. "Globalization has threatened the future growth of ...
(Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, 2016 , ... New York City based ... surgery . This surgery is a very effective way to treat obstructive sleep apnea. Dr. ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This ...
Breaking Medicine News(10 mins):